Literature DB >> 18471050

Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.

Lazaros Lekakis1, Marcos de Lima.   

Abstract

Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far to show dramatic change in the prognosis. Allogeneic stem cell transplantation using traditional myeloablative preparative regimens is not easily tolerated by the elderly and/or frailer patient, and may lead to prohibitive treatment-related mortality rates. Most patients treated in the past were younger and devoid of comorbid clinical conditions. Novel reduced-intensity regimens made allogeneic transplants applicable to the elderly, providing the benefit of the graft-versus-leukemia effect to a larger number of patients in need. Here we review the indications for allogeneic transplants in AML and discuss reduced-intensity conditioning regimens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18471050     DOI: 10.1586/14737140.8.5.785

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  4 in total

Review 1.  Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.

Authors:  S R Pingali; R E Champlin
Journal:  Bone Marrow Transplant       Date:  2015-05-18       Impact factor: 5.483

2.  Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.

Authors:  Yasuyoshi Morita; Akihisa Kanamaru; Yasushi Miyazaki; Daisuke Imanishi; Fumiharu Yagasaki; Mitsune Tanimoto; Kazutaka Kuriyama; Toru Kobayashi; Shion Imoto; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal:  Int J Hematol       Date:  2010-01-05       Impact factor: 2.490

Review 3.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?

Authors:  Lazaros J Lekakis; Brenda W Cooper; Marcos G de Lima
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

Review 4.  Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia.

Authors:  Rebecca Levin-Epstein; Caspian Oliai; Gary Schiller
Journal:  Curr Treat Options Oncol       Date:  2018-10-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.